RICHARD ROBINSON: Open Payments
NPI 1336673656 · HOOVER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,093 in 97 payments from 13 companies in 2025. Trend: 2023 $461 · 2024 $842 · 2025 $2,093
Food & beverage: $2,093
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $380 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $354 |
| Teva Pharmaceuticals USA, Inc. | 13 | $249 |
| Lundbeck LLC | 8 | $225 |
| Axsome Therapeutics, Inc. | 9 | $220 |
| ABBVIE INC. | 18 | $207 |
| Vanda Pharmaceuticals Inc. | 4 | $141 |
| Janssen Pharmaceuticals, Inc | 5 | $98 |
| Neurocrine BioSciences, Inc. | 2 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
Products named: REXULTI, CAPLYTA, Auvelity, VRAYLAR, ABILIFY MAINTENA, FANAPT, AUSTEDO XR, UZEDY.
Industry payments across AL — which companies pay providers there.
